Oxigene - mehr als eine Luftnummer?
| eröffnet am: | 10.05.11 23:07 von: | Balu4u |
| neuester Beitrag: | 24.04.21 23:33 von: | Melaniesteta |
| Anzahl Beiträge: | 226 | |
| Leser gesamt: | 37211 | |
| davon Heute: | 9 | |
bewertet mit 1 Stern |
||
|
|
||
10.05.11 23:07
#1
Balu4u
Oxigene - mehr als eine Luftnummer?
Ist Oxigene wirklich mehr als eine Luftnummer? Zumindest ist die Aktie heute 30 Prozent in den USA in die Höhe geschossen. Allerdings ist auch das Jahreshoch vom Anfang letzten Jahres ein gutes Stück weit entfernt. Wenn ich mir den max. Kurs so anssehe, sollten hier wohl bereits Resplits in der Vergangenheit durchgeführt worden sein, anders kann ich mir utopische Kurse von 240 Euro nicht erklären.
Die Homepage ist ganz interessant: http://www.oxigene.com/ ..und sollte hier der Durchbruch gelingen, dann sind hier ganz andere Kurse drin. Allerdings würde ich hier zunächst erstmal abwarten und schauen, nach so einem explosiven Kursanstieg, gibt es auch immer eine Konsolidierung. Frag ist aber immer, wann die eintritt.... ansonsten kann man immer noch einsteigen, wenn der Kurs sich ein Stockwerk höher stabilisiert hat.
200 Postings ausgeblendet.
13.03.14 21:36
#203
newliner
ach dreht der Wind wieder
dachte heute 3,50 und die kam wie jeder sieht nicht. Dann haste doch für morgen die 3,50 angesagt, nun aber morgen up in the air.....ja hast recht, du betreibst täglich deine Märchenstunde.....
Aber dich nimmt noch nicht einmal mehr deine Erzeuger für Voll, kein Wunder das dich deine Mutter dich verkauft hat. So einen Dreck wie dich holt sich keiner freiwillig ins Haus.
RAMSES oder PARADISO1 du BETRÜGER DU KRIMINELLE DRECKSAU
Aber dich nimmt noch nicht einmal mehr deine Erzeuger für Voll, kein Wunder das dich deine Mutter dich verkauft hat. So einen Dreck wie dich holt sich keiner freiwillig ins Haus.
RAMSES oder PARADISO1 du BETRÜGER DU KRIMINELLE DRECKSAU
13.03.14 21:39
#204
newliner
sag ja der labert nur
"""2305 Postings, 74 Tage RAMSES IV : morgen dann erstmal 3,50$ #197
13.03.14 20:08"""
60 Minuten später dann:
""" RAMSES IV: nachbörslich 4,30$ 21:22 #203
morgen dann up in the air"""
je nachdem wie es dann morgen läuft, kopiert er dann das eine oder andere Posting in den Thread und schreibt dazu, seht ihr.....ich der Ramses Betrüger hatte es doch gestern genau so angesagt.
Der ist echt so blöd und rafft nicht das er sich zum Ariva Clown entwickelt.....wo andere Hirn haben, hat er LUFT.....Pressluft
13.03.14 20:08"""
60 Minuten später dann:
""" RAMSES IV: nachbörslich 4,30$ 21:22 #203
morgen dann up in the air"""
je nachdem wie es dann morgen läuft, kopiert er dann das eine oder andere Posting in den Thread und schreibt dazu, seht ihr.....ich der Ramses Betrüger hatte es doch gestern genau so angesagt.
Der ist echt so blöd und rafft nicht das er sich zum Ariva Clown entwickelt.....wo andere Hirn haben, hat er LUFT.....Pressluft
13.03.14 21:59
#205
otcstar
After hours ist im Minus
http://www.nasdaq.com/symbol/oxgn/after-hours
13.03.14 22:09
#207
otcstar
High war 4,25
http://www.nasdaq.com/symbol/oxgn/after-hours
da stehen alle Kurse,
da stehen alle Kurse,
14.03.14 09:45
#211
newliner
Ramses dreht sich erneut
erst 3,50 heute, dann über 5 heute, nun wieder 3,50.....
http://www.ariva.de/forum/RAMSES-IV-497413
http://www.ariva.de/forum/RAMSES-IV-497413
19.03.14 12:01
#214
Spreeblick
weiß einer warum wir in Dt. so weit unter pari
sind? Wenn ich mir pre market US anschaue, sind wir da bei -3,49% und hier bei -16%?
Die Zahlen gestern waren ja eigentlich wie erwartet im Minus, sollten aber bei der Perspektive den Absturz nicht rechtfertigen, oder? Ich glaube, da greife ich jetzt mal wieder zu, nachdem ich letzte Woche bei meinem SL rausgekegelt wurde.
Die Zahlen gestern waren ja eigentlich wie erwartet im Minus, sollten aber bei der Perspektive den Absturz nicht rechtfertigen, oder? Ich glaube, da greife ich jetzt mal wieder zu, nachdem ich letzte Woche bei meinem SL rausgekegelt wurde.
22.07.14 23:49
#217
Balu4u
Wann kommt der nächste Schritt?
http://www.oxigene.com/product-development
01.06.15 20:23
#224
martin30sm
News
Jun 1, 2015
Previous Release
PDF Add to Briefcase
OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today provided an update on recent discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a proposed Phase 3 trial of fosbretabulin in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
FDA agreed with the company's proposal to test the combination anti-vascular regimen of fosbretabulin and bevacizumab directly against chemotherapy using progression-free survival (PFS) as the primary endpoint in a randomized, controlled registration trial.
FDA requested inclusion of a third arm, of bevacizumab alone, in the trial to further characterize the efficacy of each individual drug in the combination.
OXiGENE intends to submit an application to the FDA for a Special Protocol Assessment (SPA) later this year.
"We are extremely pleased by the agency's support for advancing to a Phase 3 trial and their guidance in defining a registration pathway for fosbretabulin in platinum-resistant ovarian cancer," said Bill Schwieterman, M.D., OXiGENE's President and CEO. "Patients with this advanced form of ovarian cancer have limited treatment options, and there are no currently approved treatment regimens that avoid the adverse effects associated with standard chemotherapy. We believe that an anti-vascular regimen could offer a new paradigm of treatment and an important addition to the available therapies for advanced ovarian cancer. Our strategy is now to prepare a full protocol for a three-arm Phase 3 trial and to pursue a SPA while we simultaneously explore funding and partnering opportunities for this promising program."
The proposed Phase 3 trial is based on the results of the GOG186I study in which the anti-vascular combination of fosbretabulin and bevacizumab showed statistically significant improvements in PFS compared to bevacizumab alone as defined by the statistical analysis plan. The benefits appeared to be particularly robust in a subset of patients with platinum-resistant disease where a post-hoc subgroup analysis of the study showed that patients who were platinum-resistant had a median PFS of 6.7 months when treated with bevacizumab and fosbretabulin compared to 3.4 months for those receiving bevacizumab alone.
In the U.S., approximately 22,000 women are diagnosed with ovarian cancer each year, of which 4,300 are resistant to platinum-based therapies. Many patients who are platinum-resistant have already experienced multiple cycles of conventional chemotherapy, and suffer from significant side effects. As the first potential non-chemotherapeutic regimen for platinum-resistant ovarian cancer, OXiGENE believes the combination of fosbretabulin and bevacizumab has the potential to avoid the side effects of standard chemotherapy and provide a more convenient dosing regimen.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapies for treatment of cancer. The company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with tumor survival and progression. The company's lead clinical product candidate, fosbretabulin, is in development as a potential treatment for solid tumors. OXi4503, its second product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.
Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
CONTACT: Investor and Media Contact:
ir@oxigene.com
650-635-7000
company logo
Source: OXiGENE, Inc.
News Provided by Acquire Media
Previous Release
PDF Add to Briefcase
OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today provided an update on recent discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a proposed Phase 3 trial of fosbretabulin in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
FDA agreed with the company's proposal to test the combination anti-vascular regimen of fosbretabulin and bevacizumab directly against chemotherapy using progression-free survival (PFS) as the primary endpoint in a randomized, controlled registration trial.
FDA requested inclusion of a third arm, of bevacizumab alone, in the trial to further characterize the efficacy of each individual drug in the combination.
OXiGENE intends to submit an application to the FDA for a Special Protocol Assessment (SPA) later this year.
"We are extremely pleased by the agency's support for advancing to a Phase 3 trial and their guidance in defining a registration pathway for fosbretabulin in platinum-resistant ovarian cancer," said Bill Schwieterman, M.D., OXiGENE's President and CEO. "Patients with this advanced form of ovarian cancer have limited treatment options, and there are no currently approved treatment regimens that avoid the adverse effects associated with standard chemotherapy. We believe that an anti-vascular regimen could offer a new paradigm of treatment and an important addition to the available therapies for advanced ovarian cancer. Our strategy is now to prepare a full protocol for a three-arm Phase 3 trial and to pursue a SPA while we simultaneously explore funding and partnering opportunities for this promising program."
The proposed Phase 3 trial is based on the results of the GOG186I study in which the anti-vascular combination of fosbretabulin and bevacizumab showed statistically significant improvements in PFS compared to bevacizumab alone as defined by the statistical analysis plan. The benefits appeared to be particularly robust in a subset of patients with platinum-resistant disease where a post-hoc subgroup analysis of the study showed that patients who were platinum-resistant had a median PFS of 6.7 months when treated with bevacizumab and fosbretabulin compared to 3.4 months for those receiving bevacizumab alone.
In the U.S., approximately 22,000 women are diagnosed with ovarian cancer each year, of which 4,300 are resistant to platinum-based therapies. Many patients who are platinum-resistant have already experienced multiple cycles of conventional chemotherapy, and suffer from significant side effects. As the first potential non-chemotherapeutic regimen for platinum-resistant ovarian cancer, OXiGENE believes the combination of fosbretabulin and bevacizumab has the potential to avoid the side effects of standard chemotherapy and provide a more convenient dosing regimen.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapies for treatment of cancer. The company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with tumor survival and progression. The company's lead clinical product candidate, fosbretabulin, is in development as a potential treatment for solid tumors. OXi4503, its second product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.
Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
CONTACT: Investor and Media Contact:
ir@oxigene.com
650-635-7000
company logo
Source: OXiGENE, Inc.
News Provided by Acquire Media